9-valent human papillomavirus recombinant vaccine
Human Papilloma Virus Infection
Explore 10 assets in Human Papilloma Virus Infection →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
University Health Network, Toronto
Modality
vaccine
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03947775CT.gov HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Human Papilloma Virus Infection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 9-valent human papillomavirus recombinant vaccine (this asset) | University Health Network, Toronto | P2 | CCC · 53 |
| Gardasil 9 Vaccine | Eunice Dube | P4 | BBB |
| Human Papillomavirus Serotype 58 Whole | Beijing Health Guard Biotechnology, Inc | P3 | BB |
| Recombinant Nonavalent Human Papillomavirus Vaccine | Beijing Health Guard Biotechnology, Inc | P3 | BB |
| Hepatitis B Virus Vaccine | Eunice Dube | P4 | BB |
| Fluorouracilum | AIDS Malignancy Consortium | P3 | BB |
| Imiquimod | AIDS Malignancy Consortium | P3 | B |
| Quadrivalent Human Papillomavirus Recombinant Vaccine | Beijing Health Guard Biotechnology, Inc | P2 | B |
| Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap | National Cancer Institute (NCI) | P2 | CCC |
+8 more in the Human Papilloma Virus Infection cohort
Other indications for 9-valent human papillomavirus recombinant vaccine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Anal Canal Carcinoma In Situ | — | P3 | BB · 66 |
| Anogenital Human Papillomavirus Infection | — | P3 | B · 60 |
| Penile Cancer | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 9-valent human papillomavirus recombinant vaccine in Human Papilloma Virus Infection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/9-valent-human-papillomavirus-recombinant-vaccine-human-papilloma-virus-infection
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →